ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

empagliflozin

Also written as “BI 10773”, “Empagliflozin” and “BI10773”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Heart Failure · Diabetes Mellitus, Type 1 · Renal Insufficiency, Chronic · Diabetes Mellitus, Lipoatrophic, led by 15 companies.

Drug pageEmpagliflozin: every studyMany companies study it; this page follows only the 124 they lead. All 404 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 27, 2015124 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheimits history only992 open or runningphase 4since Oct 27, 2015Nov 14, 2007Dec 11, 2026phase 1 · NCT07845630
ADIUMits history only40 open or runningno phasesince Mar 9, 2026Mar 9, 2026none ahead
Getz Pharmaits history only41 open or runningphase 4since Nov 27, 2020Nov 27, 2020Dec 31, 2026phase 4 · NCT05164263
Gedeon Richter Plc.its history only30 open or runningphase 1since Dec 10, 2024Dec 10, 2024none ahead
Chong Kun Dang Pharmaceuticalits history only21 open or runningphase 4since Jan 15, 2026Aug 1, 2016Aug 2027phase 4 · NCT07365358
Dong Wha Pharmaceuticalits history only20 open or runningphase 1since Apr 10, 2023Apr 10, 2023none ahead
Kobe Universityits history only20 open or runningphase 3since Jul 10, 2019Jul 10, 2019none ahead
Celltrion11 open or runningphase 3since Jun 30, 2025Jun 30, 2025Dec 2026phase 3 · NCT07093476
Dong-A STits history only10 open or runningphase 1since Dec 5, 2018Dec 5, 2018none ahead
Genuine Research Center, Egyptits history only10 open or runningphase 1since Nov 16, 2021Nov 16, 2021none ahead

Also a collaborator on its studies: Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Celltrion only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2025First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT07093476 · 171 planned · South Korea

Ahead

  1. Dec 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07093476

TargetBeta

SLC5A2 →read by rule
“An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC5A2

ProgramCompanyFurthest phaseStudies
dapagliflozinAstraZenecaphase 4133
ertugliflozinruleMerckphase 422
EnavogliflozinruleDaewoong Pharmaceuticalphase 325
vicadrostatBoehringer Ingelheimphase 316
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12

Studies

The one study Celltrion leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07093476Diabetes Mellitus, Type 2 · South Korea3RecruitingDec 2026171

How it is read

Names in the registry

  • “BI 10773”, 71 entries
  • “Empagliflozin”, 53 entries
  • “BI10773”, 7 entries
  • “Empagliflozin/Metformin”, 4 entries
  • “Empagliflozin + Linagliptin”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.